238 related articles for article (PubMed ID: 34139979)
1. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer.
Shen K; Yang L; Li FY; Zhang F; Ding LL; Yang J; Lu J; Wang NN; Wang Y
Curr Drug Targets; 2022; 23(2):145-155. PubMed ID: 34139979
[TBL] [Abstract][Full Text] [Related]
2. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
4. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
5. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
6. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
Ziadeh T; Kourie HR
Pharmacogenomics; 2021 Dec; 22(18):1237-1250. PubMed ID: 34729995
[TBL] [Abstract][Full Text] [Related]
8. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
9. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
10. Advances in the use of PARP inhibitor therapy for breast cancer.
McCann KE; Hurvitz SA
Drugs Context; 2018; 7():212540. PubMed ID: 30116283
[TBL] [Abstract][Full Text] [Related]
11. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
12. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
13. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
14. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.
Paraghamian SE; Qiu J; Hawkins GM; Zhao Z; Sun W; Fan Y; Zhang X; Suo H; Hao T; Prabhu VV; Allen JE; Zhou C; Bae-Jump V
Cancer Biol Ther; 2023 Dec; 24(1):2202104. PubMed ID: 37069726
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.
Zhang X; Huang P; Wang L; Chen S; Basappa B; Zhu T; Lobie PE; Pandey V
Cell Death Dis; 2022 Jun; 13(6):558. PubMed ID: 35725817
[TBL] [Abstract][Full Text] [Related]
16. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Janzen DM; Paik DY; Rosales MA; Yep B; Cheng D; Witte ON; Kayadibi H; Ryan CM; Jung ME; Faull K; Memarzadeh S
Mol Cancer Ther; 2013 Dec; 12(12):2917-28. PubMed ID: 24222661
[TBL] [Abstract][Full Text] [Related]
17. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
McCann KE
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
[TBL] [Abstract][Full Text] [Related]
18. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
19. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
20. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
